An Expanding Product Portfolio
Impax’s ongoing strategy to invest in R&D and to develop high-value opportunities should continue to provide the potential for growth in the future.
We currently manufacture and market 96 generic pharmaceutical products, which represent dosage variations of 29 different pharmaceutical compounds through our Generics Division; another 5 of our generic pharmaceutical products representing dosage variations of 2 different pharmaceutical compounds are marketed by our alliance agreement partners. A list of our currently marketed generic products can be found here.
Within our Specialty Pharma Division, we market:
- RYTARY® (Carbidopa and Levodopa) Extended-Release Capsules is for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication. RYTARY is not for use in patients using nonselective monoamine oxidase inhibitors (MAO) inhibitors. For more information about RYTARY, go to www.rytary.com.
- In February 2012, we licensed from AstraZeneca the exclusive U.S. commercial rights to Zomig® (zolmitriptan) tablet, orally disintegrating tablet (ODT), and nasal spray formulations pursuant to the terms of the AZ Agreement, and began sales of the Zomig® products under our label through our specialty sales force. As of May 2013, the specialty sales force has focused on the nasal spray following loss of exclusivity on the Zomig® tablet and ODT product. For more information, go to zomig.com.
We currently have 21 pending Abbreviated New Drug Applications (ANDA) at the FDA. We are also working on an additional 21 products under development with many having the potential to be first-to-file or first-to-market opportunities.